{"id":"W2058098342","doi":"10.1097/00001813-200210000-00004","title":"Epirubicin/docetaxel regimen in progressive breast cancer—a phase II study","year":2002,"lang":"en","type":"article","venue":"Anti-Cancer Drugs","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Hospital","funders":"","keywords":"Docetaxel; Epirubicin; Medicine; Regimen; Neutropenia; Metastatic breast cancer; Febrile neutropenia; Internal medicine; Breast cancer; Chemotherapy; Adverse effect; Phases of clinical research; Oncology; Surgery; Gastroenterology; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001329935,0.0003429473,0.0006970262,0.0002289428,0.0001683531,0.00001947201,0.000168637,0.00009967555,0.007635796],"category_scores_gemma":[0.000005213941,0.0002921809,0.0001220856,0.0006061312,0.000130245,0.0001794209,0.00008853129,0.0003356242,0.00008145901],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004120816,"about_ca_system_score_gemma":0.0001529507,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003120051,"about_ca_topic_score_gemma":0.0004073312,"domain_scores_codex":[0.9979452,0.00008068509,0.0004130727,0.0006138284,0.0003427158,0.0006044679],"domain_scores_gemma":[0.9990789,0.00003765973,0.0001895787,0.0003660176,0.0001189617,0.0002089047],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002622779,0.03549938,0.525524,0.0002474783,0.001705436,0.001403287,0.02667629,0.00003873937,0.009467698,0.00003687029,0.09790543,0.2988726],"study_design_scores_gemma":[0.3247644,0.0220514,0.4214526,0.002364264,0.006075961,0.0005932971,0.01028592,0.004054294,0.04457821,0.0001067729,0.1600929,0.003580014],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9758689,0.009134832,5.203664e-7,0.009139092,0.0005001883,0.001720604,0.0001246851,0.0001006468,0.003410553],"genre_scores_gemma":[0.9839664,0.002912972,0.00001861928,0.00156448,0.0007362084,0.0009263031,0.00001883998,0.00005050076,0.00980566],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3221416,"threshold_uncertainty_score":0.999953,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03439308193999131,"score_gpt":0.3809473308364784,"score_spread":0.3465542488964871,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}